Clinical trials: Hepatitis C, completed
Hepatitis C
Immune Response to Hepatitis C Virus
This study will identify and characterize immune factors involved in hepatitis C infection and elimination of the virus. Individual responses to hepatitis C infection vary; some people are able to eliminate the virus, whereas…
- Trial name
- NCT00006301
- Where
- 5 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
- Trial name
- NCT00088140
- Testing
- IDN-6556
- Where
- 15 sites in United States
- Volunteers
- 204 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatitis C
Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2
The goal of this study is to assess patients' attitudes and knowledge of Hepatitis C, analyze the variables that may influence patients' knowledge, and educate patients on Hepatitis C.
- Trial name
- NCT03320889
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- TriHealth Inc.
Hepatitis C Virus
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
Hepatitis C Virus is constantly evolving genetically, particularly in response to the immune system. This is an observational study to examine if immunosuppressants particularly calcineurin inhibitors taken by transplant patients…
- Trial name
- NCT00819026
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Survival
Metabolic Syndrome and Long-term Survival Following Liver Resection
Although hepatitis C virus (HCV) infection remains one of the main causes of hepatocellular carcinoma (HCC) worldwide, metabolic syndrome, with its increase in prevalence, has become an important and significant risk factor for…
- Trial name
- NCT05568576
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Hepatitis C, Chronic
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.
- Trial name
- NCT01508156
- Testing
- IDX719
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Genotype
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
The purposes of this study are: 1. To evaluate whether treatment with peginterferon and ribavirin for 24 weeks is sufficient to achieve a sustained virological response (SVR) rate comparable to that observed with the standard…
- Trial name
- NCT00629967
- Testing
- pegylated interferon alpha 2a and ribavirin, Pegylated interferon alfa-2a and ribavirin
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C Virus
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
The primary objective of this post-marketing surveillance study is to collect and assess data related to the safety and effectiveness of Harvoni® (ledipasvir/sofosbuvir (LDV/SOF)) treatment regimen, per the approved Korea…
- Trial name
- NCT02951364
- Testing
- LDV/SOF
- Where
- 72 sites in South Korea
- Volunteers
- 1,081 people
- Sponsor
- Gilead Sciences
Hepatitis C, Depression
Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C
In this study, depressed veterans with hepatitis C will be randomly assigned to the control group or to the exercise intervention group.
- Trial name
- NCT00643695
- Testing
- Home-based walking program, Educational intervention
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Portland VA Medical Center
Chronic Hepatitis C, Cirrhosis
Impact of Antiviral Therapy on Gastroesophageal Varices.
Hepatitis C virus (HCV) chronic infection affects 200 million people worldwide. HCV antiviral treatment has evolved rapidly since 2011.
- Trial name
- NCT02758509
- Testing
- Pegylated interferon alfa-2a + Ribavirin, Pegylated interferon alfa-2a + Ribavirin + Boceprevir, Pegylated interferon alfa-2a + Ribavirin +Telaprevir
- Volunteers
- 237 people
- Sponsor
- Parc de Salut Mar
Hepatitis C
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients…
- Trial name
- RHACE 1 (NCT02098616)
- Testing
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Morgan, MD
Hepatitis C Virus
Hepatitis C Virus and the Humoral Immune System
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection.
- Trial name
- NCT00219999
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
This trial will be done in participants who undergo transplantation of heart, kidney or lung at University of California, San Diego (UCSD) and receive a hepatitis C infected donor organ.
- Trial name
- NCT04596475
- Testing
- glecaprevir/pibrentasvir (GLE/PIB)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Hepatitis C Virus
TMC435-TiDP16-C112 - Interaction Trial With Antidepressants
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 150mg q.d. (once a day) on the steady-state pharmacokinetics of escitalopram 10 mg q.d., and vice versa.
- Trial name
- NCT01090700
- Testing
- TMC435, Escitalopram, TMC435 + Escitalopram
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis B, Hepatitis C
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
This study will define the substantial disease burden associated with viral hepatitis in India, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment…
- Trial name
- NCT01772121
- Where
- 19 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Gilead Sciences
Purpura, Thrombocytopaenic, Idiopathic
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems.
- Trial name
- NCT00359463
- Testing
- eltrombopag
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Liver Fibrosis
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop liver fibrosis leading to cirrhosis.
- Trial name
- NCT00323804
- Testing
- Peginterferon alfa-2b, Ribavirin
- Where
- 45 sites in Belgium, France
- Volunteers
- 372 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
- Trial name
- NCT02452814
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Infection
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of Ruzasvir.
- Trial name
- NCT02076100
- Testing
- Ruzasvir
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Depression
VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
The purpose of this study is to learn more about the effects of interferon and ribavirin combination therapy in people with Hepatitis C.
- Trial name
- NCT00108563
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.